EMMAC Life Sciences Group launches first Medical Cannabis Flower for UK Market

30 March 2021, London. EMMAC Life Sciences Group (‘EMMAC’), Europe’s largest independent cannabis company, is pleased to announce that its first range of unlicensed medical cannabis flower products for the UK market, is now available. The high THC flower product will be made available on prescription for a limited number of UK patients to gather patient and clinical feedback.

EMMAC is also pleased to announce a partnership with Sapphire Medical Clinics (‘Sapphire’), the UK’s largest and first Care Quality Commission (‘CQC’) registered medical cannabis clinic.  Sapphire operates a Real-World Evidence Platform which captures all patient and product data via the UK Medical Cannabis Registry for comprehensive clinical outcome analyses in this patient group.  This data-driven approach will inform EMMAC’s product development, with the objective to bring further medical cannabis flower products to market in 2021 to address identified patient requirements.

The new product range is being manufactured in the UK and will be an extension to EMMAC’s existing range of medical cannabis oil products. EMMAC’s vertically integrated business model that comprises cultivation, extraction, production and distribution means that medical cannabis flower is now more affordable for patients in the UK.

Commenting on EMMAC’s launch, Antonio Costanzo, CEO of EMMAC, said: “EMMAC is very pleased to extend its range of unlicensed medical cannabis products for the UK market, with the introduction of high-quality flower products. As a market leader we are focused on solving the key patient and physician challenges relating to the price, access and sustainability of medical cannabis products.  Driving innovation and efficiencies through our vertically integrated business model means that we have complete control of our supply chain, allowing us to maintain strict quality control whilst creating costs efficiencies that we are able to pass on to patients, while at the same time building a robust and sustainable business.”

The unlicensed medical cannabis products are GMP manufactured at Rokshaw, EMMAC’s leading UK MHRA-approved specials manufacturer.  Rokshaw, received its first commercial shipment of medical cannabis flower from Medalchemy, EMMAC’s GMP certified manufacturing site in Alicante, Spain.

To date, Rokshaw has manufactured more than 9,000 medical formulations for more than 2,600 NHS and private pharmacies and hospitals across the United Kingdom.  EMMAC acquired Rokshaw in April 2019 and is the Group’s second EU-GMP-certified laboratory.

About EMMAC Life Sciences Group

EMMAC Life Sciences Group is Europe’s leading independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC’s vision is to bring the life-enhancing potential of cannabis to the people who need it.

On 10 March 2021, EMMAC announced that it signed a definitive agreement to be acquired by Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), a leading US provider of consumer products in cannabis.  The proposed transaction, which is expected to close early in the second quarter of 2021, subject to customary closing conditions and regulatory approval, provides Curaleaf with a developed platform for entry into the European cannabis market. 

Contact:

For scientific enquiries please contact research@emmac.com

For general enquiries please contact info@emmac.com or visit www.emmac.com

 Media enquiries:

Buchanan
Henry Harrison-Topham / Jamie Hooper / Ariadna Peretz Tel: +44 (0) 20 7466 5000
emmac@buchanan.uk.com www.buchanan.uk.com

 CAUTIONARY STATEMENT

All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Group. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Group assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.